186 related articles for article (PubMed ID: 22545319)
1. Erlotinib-induced scalp perifolliculitis.
Rallis E; Petronic-Rosic V; Korfitis C
Skinmed; 2012; 10(2):70-1. PubMed ID: 22545319
[TBL] [Abstract][Full Text] [Related]
2. Folliculitis-perifolliculitis related to erlotinib therapy spares previously irradiated skin.
Acharya J; Lyon C; Bottomley DM
J Am Acad Dermatol; 2009 Jan; 60(1):154-7. PubMed ID: 19103369
[TBL] [Abstract][Full Text] [Related]
3. Hand-foot syndrome and seborrheic dermatitis-like eruption induced by erlotinib.
Benomar S; Boutayeb S; Afifi Y; Hamada S; Bouhllab J; Hassam B; Errihanni H
Dermatol Online J; 2009 Nov; 15(11):2. PubMed ID: 19951638
[TBL] [Abstract][Full Text] [Related]
4. Follicular rash during therapy with erlotinib (Tarceva).
Gerdes S; Mrowietz U
J Dtsch Dermatol Ges; 2006 Oct; 4(10):855-7. PubMed ID: 17010175
[TBL] [Abstract][Full Text] [Related]
5. Purpuric drug eruption and alopecia induced by erlotinib.
Nakamura-Wakatsuki T; Yamamoto T
Dermatol Online J; 2012 May; 18(5):16. PubMed ID: 22630586
[TBL] [Abstract][Full Text] [Related]
6. Dimorphic cutaneous manifestation of a toxic eruption due to erlotinib therapy.
Campbell TM; Brown CW
J Drugs Dermatol; 2008 Dec; 7(12):1161-3. PubMed ID: 19137770
[TBL] [Abstract][Full Text] [Related]
7. Rosaceiform eruption induced by erlotinib.
Patrizi A; Bianchi F; Neri I
Dermatol Ther; 2008 Oct; 21 Suppl 2():S43-5. PubMed ID: 18837734
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous adverse effects during therapy with an epidermal growth factor receptor (EGFR) inhibitor.
Santoro F; Cozzani E; Parodi A
J Dermatolog Treat; 2006; 17(3):160-1. PubMed ID: 16854757
[TBL] [Abstract][Full Text] [Related]
9. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.
Eames T; Landthaler M; Karrer S
Eur J Dermatol; 2007; 17(6):552-3. PubMed ID: 17951151
[No Abstract] [Full Text] [Related]
10. Epidermal growth factor receptor inhibitor-related folliculitis.
Tangri N; Al Hammadi A; Gerstein W
Dermatitis; 2007 Sep; 18(3):178-9. PubMed ID: 17725926
[No Abstract] [Full Text] [Related]
11. Papulopustular drug eruption due to an epidermal growth factor receptor inhibitors, erlotinib and cetuximab.
Bragg J; Pomeranz MK
Dermatol Online J; 2007 Jan; 13(1):1. PubMed ID: 17511934
[TBL] [Abstract][Full Text] [Related]
12. Painful annular pustular drug eruption induced by erlotinib in a patient with non-small cell lung cancer.
Lin TC; Wu PY
Cutis; 2011 Dec; 88(6):281-3. PubMed ID: 22372166
[No Abstract] [Full Text] [Related]
13. Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer.
Kiyohara Y; Yamazaki N; Kishi A
J Am Acad Dermatol; 2013 Sep; 69(3):463-72. PubMed ID: 23602600
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations.
Matsuura S; Inui N; Ozawa Y; Nakamura Y; Toyoshima M; Yasuda K; Yamada T; Shirai T; Suganuma H; Yokomura K; Suda T; Chida K
Jpn J Clin Oncol; 2011 Aug; 41(8):959-63. PubMed ID: 21715361
[TBL] [Abstract][Full Text] [Related]
15. Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib.
Guttman-Yassky E; Mita A; De Jonge M; Matthews L; McCarthy S; Iwata KK; Verweij J; Rowinsky EK; Krueger JG
Eur J Cancer; 2010 Jul; 46(11):2010-9. PubMed ID: 20621734
[TBL] [Abstract][Full Text] [Related]
16. A case of bullous dermatitis induced by erlotinib.
Oteri A; Cattaneo MT; Filipazzi V; Ferrario S; Gambaro A; Isabella L; Tosca N; Clementi E; Radice S; Piazza E
Oncologist; 2009 Dec; 14(12):1201-4. PubMed ID: 19965913
[TBL] [Abstract][Full Text] [Related]
17. Generalized xerotic dermatitis with neutrophilic spongiosis induced by erlotinib (Tarceva).
Lübbe J; Masouyé I; Dietrich PY
Dermatology; 2008; 216(3):247-9. PubMed ID: 18182820
[TBL] [Abstract][Full Text] [Related]
18. Erlotinib induced target-like purpura.
Rungtrakulchai R; Rerknimitr P
Dermatol Online J; 2014 Feb; 20(2):. PubMed ID: 24612572
[TBL] [Abstract][Full Text] [Related]
19. Radiation-induced prevention of erlotinib-induced skin rash is transient: a new aspect toward the understanding of epidermal growth factor receptor inhibitor associated cutaneous adverse effects.
Gerber PA; Enderlein E; Homey B; Muller A; Boelke E; Budach W
J Clin Oncol; 2007 Oct; 25(29):4697-8; author reply 4698-9. PubMed ID: 17925571
[No Abstract] [Full Text] [Related]
20. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
Johnson JR; Cohen M; Sridhara R; Chen YF; Williams GM; Duan J; Gobburu J; Booth B; Benson K; Leighton J; Hsieh LS; Chidambaram N; Zimmerman P; Pazdur R
Clin Cancer Res; 2005 Sep; 11(18):6414-21. PubMed ID: 16166415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]